Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

Single injection of basic fibroblast growth factor to treat severe vocal fold lesions and vocal fold paralysis

Kanazawa T., Komazawa D., Indo K., Akagi Y., Lee Y., Nakamura K.

Retrospective Study with a reported sample of 17 on Scar, published in Laryngoscope (2015) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Laryngoscope (2015)
Reported sample size
17
Source database
Europe PMC
PMID
25953726
PMCID
PMC6718003
DOI
10.1002/lary.25315
Citations
30

Abstract (original English)

Objectives/hypothesis Severe vocal fold lesions such as vocal fold sulcus, scars, and atrophy induce a communication disorder due to severe hoarseness, but a treatment has not been established. Basic fibroblast growth factor (bFGF) therapies by either four-time repeated local injections or regenerative surgery for vocal fold scar and sulcus have previously been reported, and favorable outcomes have been observed. In this study, we modified bFGF therapy using a single of bFGF injection, which may potentially be used in office procedures. Study design Retrospective chart review. Methods Five cases of vocal fold sulcus, six cases of scars, seven cases of paralysis, and 17 cases of atrophy were treated by a local injection of bFGF. The injection regimen involved injecting 50 µg of bFGF dissolved in 0.5 mL saline only once into the superficial lamina propria using a 23-gauge injection needle. Two months to 3 months after the injection, phonological outcomes were evaluated. Results The maximum phonation time (MPT), mean airflow rate, pitch range, speech fundamental frequency, jitter, and voice handicap index improved significantly after the bFGF injection. Furthermore, improvement in the MPT was significantly greater in patients with (in increasing order) vocal fold atrophy, scar, and paralysis. The improvement in the MPT among all patients was significantly correlated with age; the

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Vocal CordsCicatrixHumansLaryngeal DiseasesVocal Cord ParalysisAtrophyFibroblast Growth Factor 2Injections, IntralesionalSeverity of Illness IndexRetrospective Studies

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research